The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / C•••••• P•••••••••

G•••• P•••• P••••••• Leads Investment in C•••••• P••••••••• - G•••• P•••• P•••••••

Exit to a strategic buyerclosedannounced Jul 11, 2007closed Jul 11, 2007Fact
What happened
Target
C•••••• P•••••••••
Platform
not an add-on on record
Control
unknown
Share acquired
unknown
Industry
unknown
Target location
unknown
Seller kind
Sponsor
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • M•••••••Strategic acquirerconfirmed
    “M•••••••, QUEBEC and GREENWICH, CT – G•••• P•••• P••••••• today announced that it has acquired a majority stake in C•••••• P•••••••••, Inc. (“C••••••” or the “Company”), a leading proteomics based biopharmaceutical research company, from Thallion Pharmaceuticals (TSX: TLN).”
  • D•••• K••••Board appointeeconfirmed
    “G•••• P••••’s Adam Dolder and D•••• K•••• will join the Board of C••••••.”
Sell side
Side not stated
  • C•••••• P•••••••••Targetconfirmed
    “M•••••••, QUEBEC and GREENWICH, CT – G•••• P•••• P••••••• today announced that it has acquired a majority stake in C•••••• P•••••••••, Inc. (“C••••••” or the “Company”), a leading proteomics based biopharmaceutical research company, from Thallion Pharmaceuticals (TSX: TLN).”
Evidence
“M•••••••, QUEBEC and GREENWICH, CT – G•••• P•••• P••••••• today announced that it has acquired a majority stake in C•••••• P•••••••••, Inc. (“C••••••” or the “Company”), a leading proteomics based biopharmaceutical research company, from Thallion Pharmaceuticals (TSX: TLN).”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 20, 2026